Modulating SYNGAP
Disclosed are methods and compositions for treating a neurodevelopmental disorder in a subject in need thereof. In some aspects, the method includes administering an effective amount of an agent, wherein administering the agent modulates expression of one or more isoforms of synaptic GTPase-activating protein (SynGAP).
1. A method of treating a SynGAP-associated neurodevelopmental disorder in a subject in need thereof, the method comprising administering an effective amount of an antisense oligonucleotide (ASO), wherein administering the ASO modulates expression of one or more isoforms of synaptic GTPase-activating protein (SynGAP1), and wherein the ASO targets SynGAP2 and comprises a sequence complementary to a SynGAP2 sequence.
2. The method of claim 1 , wherein the one or more isoforms of SynGAP comprise SynGAP1 α1, SynGAP1 α2, SynGAP1 β, SynGAP1 γ, or any combination thereof.
3. The method of claim 1 , wherein the SynGAP-associated neurodevelopmental disorder comprises an intellectual disability (ID), autism spectrum disorders (ASD), epilepsy, or schizophrenia.
4. The method of claim 1 , further comprising:
(a) obtaining a sample from the subject; and
(b) assaying the expression of the one or more isoforms of SynGAP1 in the sample,
wherein the sample is a cell line, tissue, or blood,
wherein the sample is neurological tissue or neurological fluid, or
wherein the sample is hippocampal cells.
5. The method of claim 4 , wherein the sample in the subject has aberrant expression of Ras, Rap1, Rac1, or any combination thereof.
6. The method of claim 1 , wherein administering the ASO increases expression of SynGAP1 protein.
7. The method of claim 1 , wherein administering the ASO increases expression of one or more isoforms of SynGAP1.
8. The method of claim 1 , wherein the ASO comprises SEQ ID NO:18, SEQ ID NO:15, or SEQ ID NO:17.
9. The method of claim 1 , wherein the ASO consists of SEQ ID NO:18, SEQ ID NO:15, or SEQ ID NO:17.